COMPREHENSIVE
Insights across
genomics (740+ genes)
and epigenomics2â€
The only liquid profiling test integrating genome-wide
methylation coverage for enhanced clinical actionability.*^1–9
Home‍ ‍Oncology Portfolio‍ ‍Partnerships‍ ‍European Policy
FAST RESULTS
7-day turnaround
time3§
HIGHLY SENSITIVE
Detect variants
as low as 0.001% MAF2‡
* = Guardant360 Liquid CDx is under review with notified Body / EMA
MAF, mutant allele fraction; SNV, single nucleotide variant.
†Offered as a professional service. Not Applicable for EU market.
‡Reporting threshold for SNVs.
§Median turnaround time from sample receipt to results.
^Statement applies to Guardant360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx.
1. “Only” refers to FDA-approved liquid biopsy tests. Analysis performed in May 2026. 2. Guardant360 Liquid CDx Assay Specifications. May 2026. Guardant Health, Inc. Redwood City. CA. 3. Guardant Health Data on File. September 27, 2025. Guardant Health, Inc. Redwood City, CA. 4. Caris Life Sciences. Caris Assure Technical Specifications. 2024. 5. Foundation Medicine. FoundationOne Liquid CDx Technical Specifications. 2021. 6. Tempus Life Sciences. xF Liquid Biopsy Assay. 2024. 7. Tempus Life Sciences. xF+ Liquid Biopsy Assay. 2025. 8. BillionToOne, Inc. Northstar Select Assay Specifications. 2026. 9. Clemens K. Bucheit L. Forbes S, et al. Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers. Abstract 6512. Cancer Res. 2026:86(7 suppl):6512. doi:10.1158/1538-7445.AM2026-6512. Product availability may vary depending on country / region.